This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
Single vision, impact resistant spectacle lenses
Golden Optometric Group
Whittier, California, United States
Omega Vision Center, PA
Longwood, Florida, United States
Kannarr Eye Care
Pittsburg, Kansas, United States
Axial length
Test vs. control axial length change from baseline
Time frame: 72 months
Spherical equivalent refraction (SER)
Test vs. control spherical equivalent refraction (SER) change from baseline
Time frame: 72 months
Axial length
Change from baseline
Time frame: 42 months
SER
Change from baseline
Time frame: 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Haik Humble
West Monroe, Louisiana, United States
Advanced Eyecare PC
Raytown, Missouri, United States
SUNY School of Optometry
New York, New York, United States
Sacco Eye Group
Vestal, New York, United States
Dunes Eye Consultants
Dakota Dunes, South Dakota, United States
Total Eye Care
Memphis, Tennessee, United States
Dr. Bridgitte Shen Lee (PI)
Houston, Texas, United States
...and 2 more locations